Anti-SARS-CoV-2, Nucleocapsid (N) (COV19-6429)
Anti-SARS-CoV-2, Nucleocapsid (N) (COV19-6429)
Product No.: C445
- -
- -
Clone COV19-6429 Target SARS-CoV-2 Nucleocapsid (N) Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein, COVID-19 Isotype Mouse IgG1 Applications ELISA , IF |
- -
- -
Antibody DetailsProduct DetailsReactivity Species SARS-CoV-2 Host Species Mouse Product Concentration ≥1.0 mg/ml Purity ≥90% Formulation Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation This monoclonal antibody is purified by protein A chromatography or sequential differential precipitations. Storage and Handling This purified antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Applications and Recommended Usage? Quality Tested by Leinco ELISA: 1:20-1:200 IF: 1:10-1:50 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity Anti-SARS-CoV-2 (Clone COV19-6429) is specific for the nucleocapsid of SARS-CoV-2 including variants: UK B.1.1.7, SA B.1.351, Brazil P.1, B.1.617.2 (Delta), B.1.1.529 (Omicron) & BA.4. It is non-reactive with Influenza A, Influenza B, Adenovirus & MERS but does cross-react with SARS. Antigen Distribution The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2. Matched Pair Best ELISA pair (capture/conjugate), COV19-5164/COV19-6429. Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively 3, 4. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex 5. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways 6, 7. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein 8. It is also immunogenic, and antibodies 8,9 and memory T cells 10, 11 targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 12. The N protein also contributes to immune evasion by antagonizing antiviral RNAi 13, suggesting its potential value as a targeted therapeutic. Antigen DetailsNCBI Gene Bank ID Research Area Infectious Disease . Matched Pair . Seasonal and Respiratory Infections . Viral . IVD Raw Material References & Citations1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020. 2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020. 3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020. 4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006. 5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005. 6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008. 7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010. 8. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020. 9. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020. 11. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020. 12. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020. 13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020. 14. Gorshkov, Kirill, et al. "SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening." ACS pharmacology & translational science 5.1 (2022): 8-19. Link 15. Park, Jun-Gyu, et al. "Animal Models of COVID-19: Transgenic Mouse Model." SARS-CoV-2. Humana, New York, NY, 2022. 259-289. Link Technical Protocols |
Formats Available
